Antonio Sahuquillo-Torralba, Miguel Mansilla-Polo, Conrad Pujol-Marco, Mar Llamas-Velasco, Eva V Rull, Ricardo Ruiz Villaverde, Marta Ferran, Gerard Pitarch, Anna Lopez, Emma Beltran, Ana Urruticoechea-Arana, Josep Riera-Monroig, Merce Alsina, David Vidal, Isabel Belinchón Romero, Jaime Notario, José M Carrascosa, Víctor Gonzalez-Delgado, Jordi Mollet, Miquel Ribera, Fernando Gallardo
BACKGROUND: Certolizumab is an Fc-free PEGylated tumor necrosis factor-alpha (TNFα) inhibitor recently approved for the treatment of moderate-to-severe plaque psoriasis, although there is limited real-world evidence on the effectiveness and safety in patients with plaque psoriasis treated with certolizumab. The objective of this article is to determine the effectiveness, drug survival, and safety, including pregnancy, childbirth, and lactation, of certolizumab in moderate-to-severe plaque psoriasis under real-world conditions...
May 12, 2024: International Journal of Dermatology